Navigation Links
Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
Date:3/9/2009

PLYMOUTH MEETING, Pa., March 9 /PRNewswire-FirstCall/ -- Genaera Corporation (Nasdaq: GENR) today announced, in compliance with NASDAQ Marketplace Rule 4350(b)(1)(B), that the audit report included in the Company's Annual Report on Form 10-K ("Form 10-K") for the fiscal year ended December 31, 2008 contained an unqualified audit opinion from its independent registered public accounting firm, KPMG LLP, which included a "going concern" explanatory paragraph. The Company discusses this matter, including its plans to address future financing needs, in Note 1 to the financial statements included in its Form 10-K.

This disclosure is required under NASDAQ rules and does not represent any change or amendment to the Company's 2008 financial statements or to its Form 10-K which was filed on March 3, 2009 with the Securities and Exchange Commission.

About Genaera

Genaera Corporation is developing trodusquemine (MSI-1436), for type 2 diabetes and obesity currently in phase 1 clinical testing and has a fully out-licensed partnership with MedImmune, Inc. that is in phase 2 clinical testing in asthma. For further information, please see our website at http://www.genaera.com.

This announcement contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that are subject to risks and uncertainties, known and unknown. Forward-looking statements reflect management's current views and are based on certain expectations and assumptions. You may identify some of these forward-looking statements by the use of words in the statements such as "anticipate," "believe," "continue," "develop," "expect," "plan" and "potential" or other words of similar meaning. Genaera's actual results and performance could differ materially from those currently anticipated and expressed in these and other forward-looking statements as a result of a number of risk factors, including, but not limited to the risks and uncertainties discussed in Genaera's filings with the U.S. Securities and Exchange Commission, all of which are available from the Commission in its EDGAR database at www.sec.gov as well as from other sources. You are encouraged to read these reports. Given the uncertainties affecting development stage pharmaceutical companies, you are cautioned not to place undue reliance on any such forward-looking statements, any of which may turn out to be wrong due to inaccurate assumptions, unknown risks, uncertainties or other factors. Genaera does not intend (and it is not obligated) to publicly update, revise or correct these forward-looking statements or the risk factors that may relate thereto.


'/>"/>
SOURCE Genaera Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
2. Genaera Corporation Announces Licensing of Exclusive Rights to Pexiganan, a Novel Anti-Infective Drug Candidate, by Macrochem Corporation
3. Genaera Corporation Receives Audit Opinion Containing Going Concern Explanatory Paragraph
4. Xmark Comments on Genaera Cost-Saving Plan
5. Genaera Corporations 2008 Annual Stockholder Meeting Results
6. Genaera Receives Non-Compliance Notice From NASDAQ
7. Genaera to Present at Therapeutic Area Partnerships 2008
8. Genaera to Participate in Obesity Panel at RBC Capital Markets Healthcare Conference
9. Genaera to Present at BIO CEO & Investor Conference
10. Genaera Corporation Announces 2008 Financial Results
11. The ScottCare Corporation Completes Acquisition of Rozinn Electronics, a Leading Manufacturer of Cardiac Diagnostic Products
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/30/2017)... ... April 30, 2017 , ... San Francisco Dental Implant Center, considered ... updated blog post on the continual issue of the importance of second opinions. Bay ... opinion before dental surgery, but this can be a serious mistake. The new posts ...
(Date:4/29/2017)... Michigan (PRWEB) , ... April 29, 2017 , ... ... of fertility and infertility. These methods observe the naturally occurring signs and ... intercourse during the most fertile time. , Natural family planning and fertility ...
(Date:4/29/2017)... ... 2017 , ... Phytomer USA is pleased to introduce Jennifer Smith as Account ... role is to provide excellent customer service, support, training and knowledge to spa partners ... to Phytomer with a wealth of industry experience including roles as spa manager and ...
(Date:4/29/2017)... ... April 29, 2017 , ... More than half of ... are Americans doing in their leisure time that causes hearing loss? May 1 marks ... may be contributing to hearing loss, as well as schedule a hearing evaluation for ...
(Date:4/28/2017)... ... 2017 , ... An April 24th article on Yahoo! Beauty discusses the case of ... of a weight loss surgery. The woman, declaring “I will not hate my body anymore!” ... her dramatic weight loss. Dr. Feiz & Associates notes that, while it often refers its ...
Breaking Medicine News(10 mins):
(Date:4/20/2017)...  Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), ... it will be participating in the Deutsche Bank Securities ... in Boston, Massachusetts on Wednesday, ... a.m. Eastern Time. A live webcast of ... Relations website at http://investor.zimmerbiomet.com .  The webcast will ...
(Date:4/20/2017)... 20, 2017   ZappRx, Inc ., a digital health ... process, today announced it closed $25 million in Series B ... firm based in Seattle that is ... . The Series B round included participation from SR ... and GV (formerly Google Ventures). As part of ...
(Date:4/20/2017)... April 20, 2017 Research and Markets ... Contract Manufacturing Services Market Analysis By Service (Manufacturing, Research), By ... 2014 - 2025" report to their offering. ... The Latin American pharmaceutical contract ... by 2025 Low drug registration cost in Latin ...
Breaking Medicine Technology: